We are live on ! Find out more
IART icon

Integra LifeSciences

147 hedge funds and large institutions have $1.24B invested in Integra LifeSciences in 2014 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 60 increasing their positions, 44 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 44

27% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 11

12% more call options, than puts

Call options by funds: $772K | Put options by funds: $691K

5% more capital invested

Capital invested by funds: $1.18B → $1.24B (+$61M)

2% more funds holding

Funds holding: 144147 (+3)

Holders
147
Holders Change
+3
Holders Change %
+2.08%
% of All Funds
4.23%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
60
Reduced
44
Closed
11
Calls
$772K
Puts
$691K
Net Calls
+$81K
Net Calls Change
-$296K
Name Holding Trade Value Shares
Change
Change in
Stake
D.E. Shaw & Co
151
D.E. Shaw & Co
New York
-$706K -37,558 Closed
ARTA
152
A.R.T. Advisors
New York
-$590K -31,430 Closed
SCM
153
Stevens Capital Management
Pennsylvania
-$513K -27,263 Closed
First Trust Advisors
154
First Trust Advisors
Illinois
-$488K -25,967 Closed
BMCMI
155
Bryn Mawr Capital Management Inc
Pennsylvania
-$459K -24,401 Closed
Nomura Holdings
156
Nomura Holdings
Japan
-$205K -10,877 Closed
KBC Group
157
KBC Group
Belgium
-$33K -1,730 Closed
KCPG
158
Kavar Capital Partners Group
Kansas
-$1K -78 Closed

IART Hedge Fund Activity: Q2 2014 in Review

147 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q2 2014, worth a combined $1.24B — up 5.2% from $1.18B a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new IART positions and 11 closed out — a net gain of 3 holders — while 60 added to existing stakes and 44 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $18.1M. The largest seller was Boston Partners, cutting an estimated $19.1M.

  • 147 institutional investors held Integra LifeSciences (IART) as of Q2 2014, up from 144 in Q1 2014.
  • Funds reported $1.24B of Integra LifeSciences stock for Q2 2014, up 5.2% quarter-over-quarter.
  • 14 funds opened new Integra LifeSciences positions in Q2 2014 and 11 closed out, a net change of +3 holders.
  • The largest Integra LifeSciences buyer in Q2 2014 was Goldman Sachs, an estimated $18.1M added.
  • The largest Integra LifeSciences seller in Q2 2014 was Boston Partners, an estimated $19.1M sold.

Based on aggregated 13F filings for Q2 2014.